title: Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
abstract: BACKGROUND
  Antithromboxane therapy with aspirin reduces acute procedural complications of coronary angioplasty (PTCA) but has not been shown to prevent restenosis. The effect of chronic aspirin therapy on long-term clinical events after PTCA is unknown, and the utility of more specific antithromboxane agents is uncertain. The goal of this study was to assess the effects of aspirin (a nonselective inhibitor of thromboxane A2 synthesis) and sulotroban (a selective blocker of the thromboxane A2 receptor) on late clinical events and restenosis after PTCA.
  
  
  RESULTS
  Patients (n = 752) were randomly assigned to aspirin (325 mg daily), sulotroban (800 mg QID), or placebo, started within 6 hours before PTCA and continued for 6 months. The primary outcome was clinical failure at 6 months after successful PTCA, defined as (1) death, (2) myocardial infarction, or (3) restenosis associated with recurrent angina or need for repeat revascularization. Neither active treatment differed significantly from placebo in the rate of angiographic restenosis: 39% (73 of 188) in the aspirin-assigned group, 53% (100 of 189) in the sulotroban group, and 43% (85 of 196) in the placebo group. In contrast, aspirin therapy significantly improved clinical outcome in comparison to placebo (P = .046) and sulotroban (P = .006). Clinical failure occurred in 30% (49 of 162) of the aspirin group, 44% (73 of 166) of the sulotroban group, and 41% (71 of 175) of the placebo group. Myocardial infarction was significantly reduced by antithromboxane therapy: 1.2% in the aspirin group, 1.8% in the sulotroban group, and 5.7% in the placebo group (P = .030).
  
  
  CONCLUSIONS
  Thromboxane A2 blockade protects against late ischemic events after angioplasty even though angiographic restenosis is not significantly reduced. While both aspirin and sulotroban prevent the occurrence of myocardial infarction, overall clinical outcome appears superior for aspirin compared with sulotroban. Therefore, aspirin should be continued for at least 6 months after coronary angioplasty.
authors.affiliation: Cardiac Catheterization Suite, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Savage
authors.forename: S
authors.initials: S
authors.lastname: Goldberg
authors.forename: A A
authors.initials: AA
authors.lastname: Bove
authors.forename: E
authors.initials: E
authors.lastname: Deutsch
authors.forename: G
authors.initials: G
authors.lastname: Vetrovec
authors.forename: R G
authors.initials: RG
authors.lastname: Macdonald
authors.forename: T
authors.initials: T
authors.lastname: Bass
authors.forename: J R
authors.initials: JR
authors.lastname: Margolis
authors.forename: H B
authors.initials: HB
authors.lastname: Whitworth
authors.forename: A
authors.initials: A
authors.lastname: Taussig
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D012008:Recurrence; D013449:Sulfonamides / Q000627:therapeutic use*; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D013928:Thromboxane A2; C040624:sulotroban; D001241:Aspirin